Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform for Targeted Protein Degradation Enabled by Proteomics and Machine Learning
Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has raised €20.7 million (US$25 million) in a Seed financing. The round was co-led by Elaia, Pfizer Ventures and Bpifrance, as part of the InnoBio investment strategy, with participation from Wallonie Entreprendre, Argobio Studio, MACSF, The Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital.
Argobio and the Institut Pasteur Launch Enodia Therapeutics: A Biotech Company With a New Approach for Targeted Protein Degradation
Argobio and the Institut Pasteur proudly announce the launch of Enodia Therapeutics, a groundbreaking French biotech company dedicated to block and degrade disease-causing proteins for treating cancer, inflammatory diseases and viral infections. “With the convergence of an unprecedented diverse set of small molecules inhibitors of the Sec61/translocon molecular complex and advancements in generative artificial intelligence (AI), our vision is to develop novel small molecules drugs with good pharmaceuticals properties that could overcome the most critical limitations of today’s medicines,” said Yves Ribeill, CEO of Enodia Therapeutics.
